Study guide
17.2 Cardiac Masses, Thrombus, Tumor, Vegetation, and Mimics
CCI Registered Cardiac Sonographer RCS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: RCS Orientation and Clinical Context
1.1 RCS Identity, Exam Format, Application, and Retesting 1.2 Clinical History, Symptoms, Indications, and Risk Factors 1.3 Prior Studies, Serial Change, and Cross-Modality Context
2 Chapter 2: Orders, Safety, and Patient Preparation
2.1 Order Verification, Scope, and Protocol Selection 2.2 Sonographer Ergonomics and Staff Safety 2.3 Patient Preparation, Positioning, Consent, Infection Control, and Aftercare
3 Chapter 3: Reporting and 2-D TTE Foundations
3.1 Structured Findings, Significant Results, and Escalation 3.2 Standard 2-D TTE Windows, Views, and Acquisition Sequence 3.3 2-D Measurements, Foreshortening, Image Quality, and QA
4 Chapter 4: M-Mode and Doppler Acquisition
4.1 M-Mode Alignment, Timing, Measurements, and Pitfalls 4.2 Color Doppler Acquisition, Scale, Gain, and Jet Display 4.3 PW and CW Spectral Doppler Acquisition
5 Chapter 5: Advanced Doppler and Contrast
5.1 Tissue Doppler and Hemodynamic Sample Placement 5.2 Ultrasound-Enhancing Agents and LV Opacification 5.3 Agitated-Saline Studies and Intracardiac Shunts
6 Chapter 6: Stress Echocardiography
6.1 Exercise Stress Echo Protocols and Peak Imaging 6.2 Pharmacologic Stress Echo, Dobutamine, and Safety 6.3 Non-Ischemic Stress Echo and Hemodynamic Provocation
7 Chapter 7: TEE, Strain, and 3-D TEE
7.1 Assisting TEE: Preparation, Probe Safety, Views, and Complications 7.2 Strain Acquisition, Tracking Quality, and Reproducibility 7.3 3-D TEE Acquisition, Cropping, Orientation, and Artifacts
8 Chapter 8: 3-D TTE and the Aortic Valve
8.1 3-D TTE Full-Volume Acquisition and Quantitation 8.2 Aortic-Valve Anatomy, Morphology, and Function 8.3 Aortic Stenosis: Velocities, Gradients, Valve Area, and Flow States
9 Chapter 9: Aortic Regurgitation and Mitral Structure
9.1 Aortic Regurgitation Mechanisms and Integrated Severity 9.2 Mitral-Valve Anatomy, Motion, and Mechanisms 9.3 Mitral Stenosis: Planimetry, Gradients, Pressure Half-Time, and Suitability
10 Chapter 10: Mitral and Tricuspid Valve Findings
10.1 Mitral Regurgitation Mechanism, Quantitation, and Severity Integration 10.2 Tricuspid-Valve Anatomy, Structure, and Function 10.3 Tricuspid Stenosis Assessment
11 Chapter 11: Right-Sided Valve Disease
11.1 Tricuspid Regurgitation Mechanism and Severity 11.2 Pulmonic-Valve Anatomy, Structure, and Function 11.3 Pulmonic Stenosis Assessment
12 Chapter 12: Pulmonic Regurgitation and Prosthetic Valves
12.1 Pulmonic Regurgitation Mechanism and Severity 12.2 Normal Mechanical and Bioprosthetic Valve Assessment 12.3 Prosthetic Obstruction, Regurgitation, Thrombosis, and Patient–Prosthesis Mismatch
13 Chapter 13: Endocarditis and Cardiac Chambers
13.1 Valvular Endocarditis, Vegetations, Abscess, and Complications 13.2 LV and LA Size, Geometry, Volumes, Mass, and Function 13.3 RV and RA Size, Pressure, Volume, and Function
14 Chapter 14: Cardiomyopathy Phenotypes and Diastology
14.1 Dilated and Hypertrophic Cardiomyopathies, SAM, and LVOT Obstruction 14.2 Restrictive, Arrhythmogenic, and Stress Cardiomyopathies 14.3 Diastolic Function, Filling Pressure, Grading, and Pitfalls
15 Chapter 15: Systolic Function and Ischemia
15.1 LV Systolic Function, Simpson EF, Regional Motion, and Output 15.2 RV Systolic Function: TAPSE, S-prime, FAC, and Coupling 15.3 Ischemic Heart Disease, Coronary Territories, Stress Response, and Complications
16 Chapter 16: Pericardium and Great Vessels
16.1 Pericardial Effusion, Tamponade, Constriction, and Doppler Physiology 16.2 Great Vessels, Venous Return, and Pulmonary Artery Assessment 16.3 Aortic Root, Aneurysm, Dissection, and Coarctation
17 Chapter 17: Pulmonary Pressure, Masses, and Congenital Recognition
17.1 Pulmonary Hypertension, RAP/PASP Estimation, and RV Consequences 17.2 Cardiac Masses, Thrombus, Tumor, Vegetation, and Mimics 17.3 Adult Recognition of ASD, VSD, PFO, PDA, and Congenital Clues
18 Chapter 18: Devices, Strain, and Hemodynamics
18.1 ICDs, Pacemakers, Occluders, Closure Devices, and Mechanical Support 18.2 Strain Interpretation, Global Longitudinal Strain, and Disease Patterns 18.3 Cardiac Hemodynamics, Bernoulli, Continuity, Stroke Volume, and Shunts
19 Chapter 19: Infiltrative Disease and Physics Foundations
19.1 Amyloid, Sarcoid, and Other Infiltrative Disease Patterns 19.2 Ultrasound Wave Properties, Propagation, Frequency, and Wavelength 19.3 Artifact Recognition: Reverberation, Shadowing, Mirror, Refraction, and Aliasing
20 Chapter 20: Resolution and Doppler Optimization
20.1 Axial/Lateral Resolution, Frame Rate, Depth, Focus, and Trade-Offs 20.2 Spectral Doppler Optimization, Nyquist, Filters, Gain, and Angle 20.3 Color Doppler Optimization, Scale, Priority, Variance, and Gain
21 Chapter 21: 2-D, 3-D, and Contrast Optimization
21.1 2-D Optimization: Frequency, Gain, TGC, Harmonics, Depth, and Focus 21.2 3-D Optimization: Volume Rate, Stitching, Cropping, and Display 21.3 Contrast Optimization: Mechanical Index, Destruction, Replenishment, and Artifacts
17.2 Cardiac Masses, Thrombus, Tumor, Vegetation, and Mimics
Key Takeaways Explain This Topic AI
First confirm a suspected mass in orthogonal planes and describe location, attachment, size, shape, mobility, hemodynamic effect, associated findings, and image limitations.
Thrombus probability depends on stasis, injured endocardium, devices, chamber location, and prior change; echogenicity or absent contrast enhancement alone is not diagnostic.
Myxoma, fibroelastoma, malignant extension, and vegetation have typical patterns but overlap with thrombus, normal structures, degenerative tissue, and artifacts.
UEA, 3-D, TEE, CT, and CMR answer different border, attachment, vascularity, and tissue questions, while clinical data and sometimes pathology establish the final diagnosis.
Last updated: July 2026
Prove that a structure is real before naming it
A cardiac mass is first a descriptive imaging finding, not a pathologic diagnosis. Review cancer, infection, embolic event, AF, valve or device history, anticoagulation, indwelling catheter, recent infarction, surgery, and prior imaging. Acquire the suspected structure in orthogonal TTE planes and through the cardiac cycle. Change transducer position, frequency, depth, gain, focus, and insonation angle. A real structure remains anatomically coherent; reverberation, side-lobe, near-field clutter, and mirror artifact often move or disappear with the beam.
Describe chamber or valve, exact attachment, maximal dimensions, shape, border, echogenicity, homogeneity, mobility, stalk or broad base, independent motion, obstruction, valve dysfunction, and associated effusion. Record whether it is new or changed. Color assesses flow around or through a lesion but color mosaic is not tissue vascularity. Three-dimensional imaging may clarify attachment and spatial relation, while TEE improves evaluation of the LAA, atrial septum, valves, prostheses, and posterior structures. CT and CMR add tissue and extracardiac characterization. No modality feature alone makes a final histologic diagnosis.
Recognize common thrombus settings
Location Supporting setting and appearance Mimic or limitation to test
LV apex Recent anterior infarction, apical aneurysm, severe regional akinesis; mural laminated or protruding mobile mass Near-field dropout, trabeculation, false tendon, noncompaction; use an enhancing agent when the apex is not fully seen
LA or LAA AF, mitral stenosis, enlarged atrium, spontaneous echo contrast, reduced appendage flow Pectinate muscles, coumadin ridge, incomplete TTE view; TEE is usually required for confident LAA exclusion
RA or device Central line, pacing lead, foreign material, low flow, malignancy Crista terminalis, Eustachian valve, Chiari network, reverberation from a lead
Right-heart thrombus in transit Highly mobile serpiginous structure traversing RA, RV, or tricuspid valve in an embolic setting Normal mobile venous remnants; clinical instability makes immediate communication essential
Thrombus probability rises when location matches stasis or injured endocardium and prior imaging shows new development. Mobility and protrusion may increase embolic concern, but echogenicity does not reliably age a thrombus. Ultrasound-enhancing agents improve LV cavity definition and distinguish a filling defect from poorly opacified myocardium. An avascular mass usually does not enhance, yet absence of enhancement is not specific for thrombus; vegetation and some tumors can also be poorly vascularized. Do not start, stop, or recommend anticoagulation from the scanning room.
Distinguish tumor patterns without overcalling
A myxoma most often arises in the LA from a stalk near the fossa ovalis and may prolapse through the mitral valve, causing positional obstruction. It can be heterogeneous, mobile, or friable. Not every LA mass is a myxoma: thrombus, lipomatous septum, metastatic extension, and artifact remain alternatives. Papillary fibroelastoma is commonly a small mobile frondlike valvular mass; Lambl excrescences, vegetation, degenerative tissue, and thrombus overlap. Lipomatous hypertrophy thickens the interatrial septum while typically sparing the fossa ovalis, creating a dumbbell contour rather than an intracavitary tumor.
Metastatic involvement is more common than a primary malignant cardiac tumor. Look for pericardial effusion or thickening, myocardial infiltration, multiple lesions, and extension through the IVC, SVC, pulmonary veins, or great vessels. A broad-based irregular RA free-wall mass can suggest angiosarcoma, but CT, CMR, pathology, and clinical staging determine diagnosis. Tumor perfusion with an enhancing agent can support vascularity, and CMR can characterize tissue, yet overlap remains. The sonographer should report anatomy and hemodynamic effect, not announce benignity or malignancy.
Separate vegetation from sterile or normal tissue
Vegetation is typically an irregular independently mobile mass on the upstream side of a valve or infected material, accompanied at times by tissue destruction, new regurgitation, abscess, or prosthetic dehiscence. Echo cannot establish infection without clinical and microbiologic integration. Lambl excrescences, fibroelastoma, redundant chordae, calcific nodules, sutures, and nonbacterial thrombotic endocarditis can appear valvular. A negative TTE does not exclude endocarditis when suspicion is high, particularly with prosthetic valves or devices; TEE and repeat imaging may be required.
Normal structures are frequent traps. In the RA, recognize crista terminalis, Eustachian valve, and Chiari network; in the RV, moderator band and coarse trabeculation; in the LA, coumadin ridge and pectinate tissue near the appendage; in the LV, papillary muscles, false tendons, and trabeculations. Epicardial fat, caseous mitral annular calcification, prosthetic sutures, and catheter-related artifacts can also mimic masses. Confirm attachments in more than one plane and compare with expected anatomic location.
Escalate and communicate by risk
Use UEA, 3-D, TEE, CT, or CMR when the result will clarify a poorly seen border, attachment, vascularity, tissue, or extracardiac extension. State which chambers or appendages were inadequately visualized; “no mass seen” is not equivalent to exclusion in a limited study. A thrombus in transit, a mass intermittently obstructing an inflow or outflow valve, a highly mobile lesion with imminent hemodynamic risk, or destructive endocarditis complication requires immediate communication through laboratory policy. Final interpretation integrates clinical history, cultures, multimodality imaging, treatment response, surgery, or pathology.
Preserve uncertainty during follow-up
Serial behavior can refine probability without supplying pathology. Resolution during clinician-directed anticoagulation supports thrombus; growth, invasion, vascularity, or extracardiac extension raises tumor concern; new valve destruction with bacteremia raises infection concern. Confirm that plane, enhancement, and loading are comparable before calling change. Record the observation and relevant treatment interval, while leaving medication, biopsy, surgery, and final diagnostic decisions to the clinical team.
Location is evidence, not a diagnosis
A left-atrial mass near the fossa ovalis may suggest myxoma, while an apical mass in an akinetic LV may suggest thrombus. Neither pattern is definitive until mimics, other planes, clinical context, and appropriate advanced imaging are reconciled.